Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease, which is characterized by the degeneration of motor neurons in the motor cortex and the spinal cord and subsequently by muscle atrophy. To date, numerous gene mutations have been linked to both sporadic and familial ALS, but the effort of many experimental groups to develop a suitable therapy has not, as of yet, proven successful. The original focus was on the degenerating motor neurons, when researchers tried to understand the pathological mechanisms that cause their slow death. However, it was soon discovered that ALS is a complicated and diverse pathology, where not only neurons, but also other cell types, play a crucial role via the so-called non-cell autonomous effect, which strongly deteriorates neuronal conditions. Subsequently, variable glia-based in vitro and in vivo models of ALS were established and used for brand-new experimental and clinical approaches. Such a shift towards glia soon bore its fruit in the form of several clinical studies, which more or less successfully tried to ward the unfavourable prognosis of ALS progression off. In this review, we aimed to summarize current knowledge regarding the involvement of each glial cell type in the progression of ALS, currently available treatments, and to provide an overview of diverse clinical trials covering pharmacological approaches, gene, and cell therapies.

2nd Faculty of Medicine Charles University 15006 Prague Czech Republic

Department of Cellular Neurophysiology Institute of Experimental Medicine Academy of Sciences of the Czech Republic 14200 Prague Czech Republic

Zobrazit více v PubMed

Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197–206. doi: 10.1038/nature20413. PubMed DOI PMC

Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat. Rev. Neurosci. 2006;7:710–723. doi: 10.1038/nrn1971. PubMed DOI

Wolf J., Safer A., Wohrle J.C., Palm F., Nix W.A., Maschke M., Grau A.J. Variability and prognostic relevance of different phenotypes in amyotrophic lateral sclerosis—Data from a population-based registry. J. Neurol. Sci. 2014;345:164–167. doi: 10.1016/j.jns.2014.07.033. PubMed DOI

Huisman M.H., de Jong S.W., van Doormaal P.T., Weinreich S.S., Schelhaas H.J., van der Kooi A.J., de Visser M., Veldink J.H., van den Berg L.H. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J. Neurol. Neurosurg. Psychiatry. 2011;82:1165–1170. doi: 10.1136/jnnp.2011.244939. PubMed DOI

Logroscino G., Traynor B.J., Hardiman O., Chio A., Mitchell D., Swingler R.J., Millul A., Benn E., Beghi E. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry. 2010;81:385–390. doi: 10.1136/jnnp.2009.183525. PubMed DOI PMC

Pupillo E., Messina P., Logroscino G., Beghi E., Group S. Long-term survival in amyotrophic lateral sclerosis: A population-based study. Ann. Neurol. 2014;75:287–297. doi: 10.1002/ana.24096. PubMed DOI

Qureshi M., Schoenfeld D.A., Paliwal Y., Shui A., Cudkowicz M.E. The natural history of ALS is changing: Improved survival. Amyotroph. Lateral Scler. 2009;10:324–331. doi: 10.3109/17482960903009054. PubMed DOI

Gamez J., Corbera-Bellalta M., Nogales G., Raguer N., Garcia-Arumi E., Badia-Canto M., Llado-Carbo E., Alvarez-Sabin J. Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: Should all sporadic ALS cases also be screened for SOD1? J. Neurol. Sci. 2006;247:21–28. doi: 10.1016/j.jns.2006.03.006. PubMed DOI

Cooper-Knock J., Hewitt C., Highley J.R., Brockington A., Milano A., Man S., Martindale J., Hartley J., Walsh T., Gelsthorpe C., et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 2012;135:751–764. doi: 10.1093/brain/awr365. PubMed DOI PMC

Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O’Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62. doi: 10.1038/362059a0. PubMed DOI

Gowers W.R. A Manual of Diseases of the Nervous System. Churchill; London, UK: 1886–1888.

Traynor B.J., Codd M.B., Corr B., Forde C., Frost E., Hardiman O. Amyotrophic Lateral Sclerosis Mimic Syndromes: A Population-Based Study. JAMA Neurol. 2000;57:109–113. doi: 10.1001/archneur.57.1.109. PubMed DOI

Kuipers-Upmeijer J., de Jager A.E., Hew J.M., Snoek J.W., van Weerden T.W. Primary lateral sclerosis: Clinical, neurophysiological, and magnetic resonance findings. J. Neurol. Neurosurg. Psychiatry. 2001;71:615–620. doi: 10.1136/jnnp.71.5.615. PubMed DOI PMC

Riad S.M., Hathout H., Huang J.C. High T2 signal in primary lateral sclerosis supports the topographic distribution of fibers in the corpus callosum: Assessing disease in the primary motor segment. AJNR Am. J. Neuroradiol. 2011;32:E61–E64. doi: 10.3174/ajnr.A2067. PubMed DOI PMC

Kim W.K., Liu X., Sandner J., Pasmantier M., Andrews J., Rowland L.P., Mitsumoto H. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology. 2009;73:1686–1692. doi: 10.1212/WNL.0b013e3181c1dea3. PubMed DOI PMC

Riku Y., Atsuta N., Yoshida M., Tatsumi S., Iwasaki Y., Mimuro M., Watanabe H., Ito M., Senda J., Nakamura R., et al. Differential motor neuron involvement in progressive muscular atrophy: A comparative study with amyotrophic lateral sclerosis. BMJ Open. 2014;4:e005213. doi: 10.1136/bmjopen-2014-005213. PubMed DOI PMC

Tard C., Defebvre L., Moreau C., Devos D., Danel-Brunaud V. Clinical features of amyotrophic lateral sclerosis and their prognostic value. Rev. Neurol. (Paris) 2017;173:263–272. doi: 10.1016/j.neurol.2017.03.029. PubMed DOI

Paganoni S., Macklin E.A., Lee A., Murphy A., Chang J., Zipf A., Cudkowicz M., Atassi N. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) Amyotroph. Lateral Scler. Front. Degener. 2014;15:453–456. doi: 10.3109/21678421.2014.903974. PubMed DOI PMC

Reichenstein I., Eitan C., Diaz-Garcia S., Haim G., Magen I., Siany A., Hoye M.L., Rivkin N., Olender T., Toth B., et al. Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology. Sci. Transl. Med. 2019;11 doi: 10.1126/scitranslmed.aav5264. PubMed DOI PMC

Allen S.P., Hall B., Woof R., Francis L., Gatto N., Shaw A.C., Myszczynska M., Hemingway J., Coldicott I., Willcock A., et al. C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain. 2019;142:3771–3790. doi: 10.1093/brain/awz302. PubMed DOI PMC

Norante R.P., Peggion C., Rossi D., Martorana F., De Mario A., Lia A., Massimino M.L., Bertoli A. ALS-Associated SOD1(G93A) Decreases SERCA Pump Levels and Increases Store-Operated Ca(2+) Entry in Primary Spinal Cord Astrocytes from a Transgenic Mouse Model. Int. J. Mol. Sci. 2019;20 doi: 10.3390/ijms20205151. PubMed DOI PMC

Halpern M., Brennand K.J., Gregory J. Examining the relationship between astrocyte dysfunction and neurodegeneration in ALS using hiPSCs. Neurobiol. Dis. 2019;132:104562. doi: 10.1016/j.nbd.2019.104562. PubMed DOI PMC

Eisen A., Braak H., Del Tredici K., Lemon R., Ludolph A.C., Kiernan M.C. Cortical influences drive amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2017;88:917–924. doi: 10.1136/jnnp-2017-315573. PubMed DOI

Eisen A., Kim S., Pant B. Amyotrophic lateral sclerosis (ALS): A phylogenetic disease of the corticomotoneuron? Muscle Nerve. 1992;15:219–224. doi: 10.1002/mus.880150215. PubMed DOI

Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-Sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp. Neurol. 2004;185:232–240. doi: 10.1016/j.expneurol.2003.10.004. PubMed DOI

Ravits J., Paul P., Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology. 2007;68:1571–1575. doi: 10.1212/01.wnl.0000260965.20021.47. PubMed DOI

Ravits J.M., La Spada A.R. ALS motor phenotype heterogeneity, focality, and spread: Deconstructing motor neuron degeneration. Neurology. 2009;73:805–811. doi: 10.1212/WNL.0b013e3181b6bbbd. PubMed DOI PMC

Geevasinga N., Menon P., Ozdinler P.H., Kiernan M.C., Vucic S. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat. Rev. Neurol. 2016;12:651–661. doi: 10.1038/nrneurol.2016.140. PubMed DOI

Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130–133. doi: 10.1126/science.1134108. PubMed DOI

Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248–264. doi: 10.1038/nrn3430. PubMed DOI

DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–256. doi: 10.1016/j.neuron.2011.09.011. PubMed DOI PMC

Ash P.E., Bieniek K.F., Gendron T.F., Caulfield T., Lin W.L., Dejesus-Hernandez M., van Blitterswijk M.M., Jansen-West K., Paul J.W., 3rd, Rademakers R., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639–646. doi: 10.1016/j.neuron.2013.02.004. PubMed DOI PMC

Mori K., Weng S.-M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C., et al. The C9orf72 GGGGCC repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS. Science. 2013;339:1335–1338. doi: 10.1126/science.1232927. PubMed DOI

Al-Sarraj S., King A., Troakes C., Smith B., Maekawa S., Bodi I., Rogelj B., Al-Chalabi A., Hortobagyi T., Shaw C.E. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 2011;122:691–702. doi: 10.1007/s00401-011-0911-2. PubMed DOI

Lee J., Hyeon S.J., Im H., Ryu H., Kim Y., Ryu H. Astrocytes and Microglia as Non-cell Autonomous Players in the Pathogenesis of ALS. Exp. Neurobiol. 2016;25:233–240. doi: 10.5607/en.2016.25.5.233. PubMed DOI PMC

Van Damme P., Robberecht W., Van Den Bosch L. Modelling amyotrophic lateral sclerosis: Progress and possibilities. Dis. Model. Mech. 2017;10:537–549. doi: 10.1242/dmm.029058. PubMed DOI PMC

Lutz C. Mouse models of ALS: Past, present and future. Brain Res. 2018;1693:1–10. doi: 10.1016/j.brainres.2018.03.024. PubMed DOI

Philips T., Rothstein J.D. Rodent Models of Amyotrophic Lateral Sclerosis. Curr. Protoc. Pharmacol. 2015;69:5.67.1–5.67.21. doi: 10.1002/0471141755.ph0567s69. PubMed DOI PMC

Joyce P.I., Fratta P., Fisher E.M., Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: Recent advances in understanding disease toward the development of clinical treatments. Mamm. Genome. 2011;22:420–448. doi: 10.1007/s00335-011-9339-1. PubMed DOI

Ludolph A.C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J.P., Mead R., Niessen H.G., Petri S., Pradat P.F., et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral Scler. 2010;11:38–45. doi: 10.3109/17482960903545334. PubMed DOI

Rosen D.R., Sapp P., O’Regan J., McKenna-Yasek D., Schlumpf K.S., Haines J.L., Gusella J.F., Horvitz H.R., Brown R.H., Jr. Genetic linkage analysis of familial amyotrophic lateral sclerosis using human chromoso- me 21 microsatellite DNA markers. Am J Med Genet. 1994;51:61–69. doi: 10.1002/ajmg.1320510114. PubMed DOI

Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772–1775. doi: 10.1126/science.8209258. PubMed DOI

Zwiegers P., Lee G., Shaw C.A. Reduction in hSOD1 copy number significantly impacts ALS phenotype presentation in G37R (line 29) mice: Implications for the assessment of putative therapeutic agents. J. Negat. Results Biomed. 2014;13:14. doi: 10.1186/1477-5751-13-14. PubMed DOI PMC

Lepore A.C. Intraspinal cell transplantation for targeting cervical ventral horn in amyotrophic lateral sclerosis and traumatic spinal cord injury. J. Vis. Exp. 2011;18:3069. doi: 10.3791/3069. PubMed DOI PMC

Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) Proc. Natl. Acad. Sci. USA. 2002;99:1604–1609. doi: 10.1073/pnas.032539299. PubMed DOI PMC

Rehorova M., Vargova I., Forostyak S., Vackova I., Turnovcova K., Kupcova Skalnikova H., Vodicka P., Kubinova S., Sykova E., Jendelova P. A Combination of Intrathecal and Intramuscular Application of Human Mesenchymal Stem Cells Partly Reduces the Activation of Necroptosis in the Spinal Cord of SOD1(G93A) Rats. Stem Cells Transl. Med. 2019;8:535–547. doi: 10.1002/sctm.18-0223. PubMed DOI PMC

Gong Y.H., Parsadanian A.S., Andreeva A., Snider W.D., Elliott J.L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 2000;20:660–665. doi: 10.1523/JNEUROSCI.20-02-00660.2000. PubMed DOI PMC

Pramatarova A., Laganière J., Roussel J., Brisebois K., Rouleau G.A. Neuron-Specific Expression of Mutant Superoxide Dismutase 1 in Transgenic Mice Does Not Lead to Motor Impairment. J. Neurosci. 2001;21:3369–3374. doi: 10.1523/JNEUROSCI.21-10-03369.2001. PubMed DOI PMC

Lino M.M., Schneider C., Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 2002;22:4825–4832. doi: 10.1523/JNEUROSCI.22-12-04825.2002. PubMed DOI PMC

Beers D.R., Henkel J.S., Xiao Q., Zhao W., Wang J., Yen A.A., Siklos L., McKercher S.R., Appel S.H. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2006;103:16021–16026. doi: 10.1073/pnas.0607423103. PubMed DOI PMC

Jaarsma D., Teuling E., Haasdijk E.D., De Zeeuw C.I., Hoogenraad C.C. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J. Neurosci. 2008;28:2075–2088. doi: 10.1523/JNEUROSCI.5258-07.2008. PubMed DOI PMC

Turner B.J., Ackerley S., Davies K.E., Talbot K. Dismutase-competent SOD1 mutant accumulation in myelinating Schwann cells is not detrimental to normal or transgenic ALS model mice. Hum. Mol. Genet. 2010;19:815–824. doi: 10.1093/hmg/ddp550. PubMed DOI

Philips T., Rothstein J.D. Glial cells in amyotrophic lateral sclerosis. Pt BExp. Neurol. 2014;262:111–120. doi: 10.1016/j.expneurol.2014.05.015. PubMed DOI PMC

Lemmens R., Van Hoecke A., Hersmus N., Geelen V., D’Hollander I., Thijs V., Van Den Bosch L., Carmeliet P., Robberecht W. Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum. Mol. Genet. 2007;16:2359–2365. doi: 10.1093/hmg/ddm193. PubMed DOI

Babin P.J., Goizet C., Raldua D. Zebrafish models of human motor neuron diseases: Advantages and limitations. Prog. Neurobiol. 2014;118:36–58. doi: 10.1016/j.pneurobio.2014.03.001. PubMed DOI

Tsao W., Jeong Y.H., Lin S., Ling J., Price D.L., Chiang P.M., Wong P.C. Rodent models of TDP-43: Recent advances. Brain Res. 2012;1462:26–39. doi: 10.1016/j.brainres.2012.04.031. PubMed DOI PMC

Zhou H., Huang C., Chen H., Wang D., Landel C.P., Xia P.Y., Bowser R., Liu Y.J., Xia X.G. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet. 2010;6:e1000887. doi: 10.1371/journal.pgen.1000887. PubMed DOI PMC

Tong J., Huang C., Bi F., Wu Q., Huang B., Liu X., Li F., Zhou H., Xia X.G. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats. EMBO J. 2013;32:1917–1926. doi: 10.1038/emboj.2013.122. PubMed DOI PMC

Hatzipetros T., Bogdanik L.P., Tassinari V.R., Kidd J.D., Moreno A.J., Davis C., Osborne M., Austin A., Vieira F.G., Lutz C., et al. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2014;1584:59–72. doi: 10.1016/j.brainres.2013.10.013. PubMed DOI

Laird A.S., Van Hoecke A., De Muynck L., Timmers M., Van den Bosch L., Van Damme P., Robberecht W. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE. 2010;5:e13368. doi: 10.1371/journal.pone.0013368. PubMed DOI PMC

Koppers M., Blokhuis A.M., Westeneng H.J., Terpstra M.L., Zundel C.A., Vieira de Sa R., Schellevis R.D., Waite A.J., Blake D.J., Veldink J.H., et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 2015;78:426–438. doi: 10.1002/ana.24453. PubMed DOI PMC

O’Rourke J.G., Bogdanik L., Yáñez A., Lall D., Wolf A.J., Muhammad A.K., Ho R., Carmona S., Vit J.P., Zarrow J., et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324–1329. doi: 10.1126/science.aaf1064. PubMed DOI PMC

Dickinson M.E., Flenniken A.M., Ji X., Teboul L., Wong M.D., White J.K., Meehan T.F., Weninger W.J., Westerberg H., Adissu H., et al. High-throughput discovery of novel developmental phenotypes. Nature. 2016;537:508–514. doi: 10.1038/nature19356. PubMed DOI PMC

Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-Nejad P., Drenner K., Schulte D., et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90:535–550. doi: 10.1016/j.neuron.2016.04.006. PubMed DOI PMC

O’Rourke J.G., Bogdanik L., Muhammad A., Gendron T.F., Kim K.J., Austin A., Cady J., Liu E.Y., Zarrow J., Grant S., et al. C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron. 2015;88:892–901. doi: 10.1016/j.neuron.2015.10.027. PubMed DOI PMC

Peters O.M., Cabrera G.T., Tran H., Gendron T.F., McKeon J.E., Metterville J., Weiss A., Wightman N., Salameh J., Kim J., et al. Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. Neuron. 2015;88:902–909. doi: 10.1016/j.neuron.2015.11.018. PubMed DOI PMC

Liu Y., Pattamatta A., Zu T., Reid T., Bardhi O., Borchelt D.R., Yachnis A.T., Ranum L.P. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron. 2016;90:521–534. doi: 10.1016/j.neuron.2016.04.005. PubMed DOI

Batra R., Lee C.W. Mouse Models of C9orf72 Hexanucleotide Repeat Expansion in Amyotrophic Lateral Sclerosis/ Frontotemporal Dementia. Front. Cell. Neurosci. 2017;11:196. doi: 10.3389/fncel.2017.00196. PubMed DOI PMC

Matus S., Medinas D.B., Hetz C. Common ground: Stem cell approaches find shared pathways underlying ALS. Cell Stem Cell. 2014;14:697–699. doi: 10.1016/j.stem.2014.05.001. PubMed DOI

Maury Y., Come J., Piskorowski R.A., Salah-Mohellibi N., Chevaleyre V., Peschanski M., Martinat C., Nedelec S. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat. Biotechnol. 2015;33:89–96. doi: 10.1038/nbt.3049. PubMed DOI

Moser J.M., Bigini P., Schmitt-John T. The wobbler mouse, an ALS animal model. Mol. Genet. Genom. 2013;288:207–229. doi: 10.1007/s00438-013-0741-0. PubMed DOI PMC

Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14:1105–1116. doi: 10.1016/0896-6273(95)90259-7. PubMed DOI

Jonsson P.A., Graffmo K.S., Andersen P.M., Brannstrom T., Lindberg M., Oliveberg M., Marklund S.L. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain. 2006;129:451–464. doi: 10.1093/brain/awh704. PubMed DOI

Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., et al. ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions. Neuron. 1997;18:327–338. doi: 10.1016/S0896-6273(00)80272-X. PubMed DOI

Ripps M.E., Huntley G.W., Hof P.R., Morrison J.H., Gordon J.W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 1995;92:689–693. doi: 10.1073/pnas.92.3.689. PubMed DOI PMC

Marcuzzo S., Zucca I., Mastropietro A., de Rosbo N.K., Cavalcante P., Tartari S., Bonanno S., Preite L., Mantegazza R., Bernasconi P. Hind limb muscle atrophy precedes cerebral neuronal degeneration in G93A-SOD1 mouse model of amyotrophic lateral sclerosis: A longitudinal MRI study. Exp. Neurol. 2011;231:30–37. doi: 10.1016/j.expneurol.2011.05.007. PubMed DOI

Jonsson P.A., Ernhill K., Andersen P.M., Bergemalm D., Brannstrom T., Gredal O., Nilsson P., Marklund S.L. Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain. 2004;127:73–88. doi: 10.1093/brain/awh005. PubMed DOI

Chang-Hong R., Wada M., Koyama S., Kimura H., Arawaka S., Kawanami T., Kurita K., Kadoya T., Aoki M., Itoyama Y., et al. Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2005;194:203–211. doi: 10.1016/j.expneurol.2005.02.011. PubMed DOI

Wang J., Xu G., Gonzales V., Coonfield M., Fromholt D., Copeland N.G., Jenkins N.A., Borchelt D.R. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol. Dis. 2002;10:128–138. doi: 10.1006/nbdi.2002.0498. PubMed DOI

Deng H.X., Jiang H., Fu R., Zhai H., Shi Y., Liu E., Hirano M., Dal Canto M.C., Siddique T. Molecular dissection of ALS-associated toxicity of SOD1 in transgenic mice using an exon-fusion approach. Hum. Mol. Genet. 2008;17:2310–2319. doi: 10.1093/hmg/ddn368. PubMed DOI PMC

Wang J., Ma J.H., Giffard R.G. Overexpression of copper/zinc superoxide dismutase decreases ischemia-like astrocyte injury. Free Radic. Biol. Med. 2005;38:1112–1118. doi: 10.1016/j.freeradbiomed.2005.01.010. PubMed DOI

Watanabe Y., Yasui K., Nakano T., Doi K., Fukada Y., Kitayama M., Ishimoto M., Kurihara S., Kawashima M., Fukuda H., et al. Mouse motor neuron disease caused by truncated SOD1 with or without C-terminal modification. Brain Res. Mol. Brain Res. 2005;135:12–20. doi: 10.1016/j.molbrainres.2004.11.019. PubMed DOI

Nagai M., Aoki M., Miyoshi I., Kato M., Pasinelli P., Kasai N., Brown R.H., Jr., Itoyama Y. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: Associated mutations develop motor neuron disease. J. Neurosci. 2001;21:9246–9254. doi: 10.1523/JNEUROSCI.21-23-09246.2001. PubMed DOI PMC

Ramesh T., Lyon A.N., Pineda R.H., Wang C., Janssen P.M., Canan B.D., Burghes A.H., Beattie C.E. A genetic model of amyotrophic lateral sclerosis in zebrafish displays phenotypic hallmarks of motoneuron disease. Dis. Model. Mech. 2010;3:652–662. doi: 10.1242/dmm.005538. PubMed DOI PMC

Watson M.R., Lagow R.D., Xu K., Zhang B., Bonini N.M. A drosophila model for amyotrophic lateral sclerosis reveals motor neuron damage by human SOD1. J. Biol. Chem. 2008;283:24972–24981. doi: 10.1074/jbc.M804817200. PubMed DOI PMC

Wang J., Farr G.W., Hall D.H., Li F., Furtak K., Dreier L., Horwich A.L. An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. PLoS Genet. 2009;5:e1000350. doi: 10.1371/journal.pgen.1000350. PubMed DOI PMC

Awano T., Johnson G.S., Wade C.M., Katz M.L., Johnson G.C., Taylor J.F., Perloski M., Biagi T., Baranowska I., Long S., et al. Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2009;106:2794–2799. doi: 10.1073/pnas.0812297106. PubMed DOI PMC

Wegorzewska I., Bell S., Cairns N.J., Miller T.M., Baloh R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809–18814. doi: 10.1073/pnas.0908767106. PubMed DOI PMC

Stallings N.R., Puttaparthi K., Luther C.M., Burns D.K., Elliott J.L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 2010;40:404–414. doi: 10.1016/j.nbd.2010.06.017. PubMed DOI

Swarup V., Phaneuf D., Bareil C., Robertson J., Rouleau G.A., Kriz J., Julien J.P. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134:2610–2626. doi: 10.1093/brain/awr159. PubMed DOI

Xu Y.F., Gendron T.F., Zhang Y.J., Lin W.L., D’Alton S., Sheng H., Casey M.C., Tong J., Knight J., Yu X., et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 2010;30:10851–10859. doi: 10.1523/JNEUROSCI.1630-10.2010. PubMed DOI PMC

Arnold E.S., Ling S.C., Huelga S.C., Lagier-Tourenne C., Polymenidou M., Ditsworth D., Kordasiewicz H.B., McAlonis-Downes M., Platoshyn O., Parone P.A., et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. USA. 2013;110:E736–E745. doi: 10.1073/pnas.1222809110. PubMed DOI PMC

Voigt A., Herholz D., Fiesel F.C., Kaur K., Muller D., Karsten P., Weber S.S., Kahle P.J., Marquardt T., Schulz J.B. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS ONE. 2010;5:e12247. doi: 10.1371/journal.pone.0012247. PubMed DOI PMC

Lu Y., Ferris J., Gao F.B. Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Mol. Brain. 2009;2:30. doi: 10.1186/1756-6606-2-30. PubMed DOI PMC

Liachko N.F., Guthrie C.R., Kraemer B.C. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J. Neurosci. 2010;30:16208–16219. doi: 10.1523/JNEUROSCI.2911-10.2010. PubMed DOI PMC

Igaz L.M., Kwong L.K., Lee E.B., Chen-Plotkin A., Swanson E., Unger T., Malunda J., Xu Y., Winton M.J., Trojanowski J.Q., et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Investig. 2011;121:726–738. doi: 10.1172/JCI44867. PubMed DOI PMC

Janssens J., Wils H., Kleinberger G., Joris G., Cuijt I., Ceuterick-de Groote C., Van Broeckhoven C., Kumar-Singh S. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol. Neurobiol. 2013;48:22–35. doi: 10.1007/s12035-013-8427-5. PubMed DOI PMC

Huang C., Tong J., Bi F., Zhou H., Xia X.G. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J. Clin. Investig. 2012;122:107–118. doi: 10.1172/JCI59130. PubMed DOI PMC

Boillée S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia. Science. 2006;312:1389–1392. doi: 10.1126/science.1123511. PubMed DOI

Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013;16:571–579. doi: 10.1038/nn.3357. PubMed DOI PMC

Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008;11:251–253. doi: 10.1038/nn2047. PubMed DOI PMC

Ralph G.S., Radcliffe P.A., Day D.M., Carthy J.M., Leroux M.A., Lee D.C.P., Wong L.-F., Bilsland L.G., Greensmith L., Kingsman S.M., et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 2005;11:429–433. doi: 10.1038/nm1205. PubMed DOI

Rostalski H., Leskela S., Huber N., Katisko K., Cajanus A., Solje E., Marttinen M., Natunen T., Remes A.M., Hiltunen M., et al. Astrocytes and Microglia as Potential Contributors to the Pathogenesis of C9orf72 Repeat Expansion-Associated FTLD and ALS. Front. Neurosci. 2019;13:486. doi: 10.3389/fnins.2019.00486. PubMed DOI PMC

Geloso M.C., Corvino V., Marchese E., Serrano A., Michetti F., D’Ambrosi N. The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches. Front. Aging Neurosci. 2017;9:242. doi: 10.3389/fnagi.2017.00242. PubMed DOI PMC

Clarke L.E., Liddelow S.A., Chakraborty C., Munch A.E., Heiman M., Barres B.A. Normal aging induces A1-like astrocyte reactivity. Proc. Natl. Acad. Sci. USA. 2018;115:E1896–E1905. doi: 10.1073/pnas.1800165115. PubMed DOI PMC

Liddelow S.A., Guttenplan K.A., Clarke L.E., Bennett F.C., Bohlen C.J., Schirmer L., Bennett M.L., Munch A.E., Chung W.S., Peterson T.C., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–487. doi: 10.1038/nature21029. PubMed DOI PMC

Mahmoud S., Gharagozloo M., Simard C., Gris D. Astrocytes Maintain Glutamate Homeostasis in the CNS by Controlling the Balance between Glutamate Uptake and Release. Cells. 2019;8 doi: 10.3390/cells8020184. PubMed DOI PMC

Lepore A.C., Rauck B., Dejea C., Pardo A.C., Rao M.S., Rothstein J.D., Maragakis N.J. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 2008;11:1294–1301. doi: 10.1038/nn.2210. PubMed DOI PMC

Qian K., Huang H., Peterson A., Hu B., Maragakis N.J., Ming G.L., Chen H., Zhang S.C. Sporadic ALS Astrocytes Induce Neuronal Degeneration In Vivo. Stem Cell Rep. 2017;8:843–855. doi: 10.1016/j.stemcr.2017.03.003. PubMed DOI PMC

Haidet-Phillips A.M., Doreswamy A., Gross S.K., Tang X., Campanelli J.T., Maragakis N.J. Human glial progenitor engraftment and gene expression is independent of the ALS environment. Exp. Neurol. 2015;264:188–199. doi: 10.1016/j.expneurol.2014.12.011. PubMed DOI PMC

Boston-Howes W., Gibb S.L., Williams E.O., Pasinelli P., Brown R.H., Jr., Trotti D. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J. Biol. Chem. 2006;281:14076–14084. doi: 10.1074/jbc.M600653200. PubMed DOI

Gibb S.L., Boston-Howes W., Lavina Z.S., Gustincich S., Brown R.H., Jr., Pasinelli P., Trotti D. A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. J. Biol. Chem. 2007;282:32480–32490. doi: 10.1074/jbc.M704314200. PubMed DOI

Foran E., Bogush A., Goffredo M., Roncaglia P., Gustincich S., Pasinelli P., Trotti D. Motor neuron impairment mediated by a sumoylated fragment of the glial glutamate transporter EAAT2. Glia. 2011;59:1719–1731. doi: 10.1002/glia.21218. PubMed DOI PMC

Agarwal A., Wu P.H., Hughes E.G., Fukaya M., Tischfield M.A., Langseth A.J., Wirtz D., Bergles D.E. Transient Opening of the Mitochondrial Permeability Transition Pore Induces Microdomain Calcium Transients in Astrocyte Processes. Neuron. 2017;93:587–605.e7. doi: 10.1016/j.neuron.2016.12.034. PubMed DOI PMC

Rosenblum L.T., Shamamandri-Markandaiah S., Ghosh B., Foran E., Lepore A.C., Pasinelli P., Trotti D. Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS. Exp. Neurol. 2017;292:145–153. doi: 10.1016/j.expneurol.2017.03.014. PubMed DOI PMC

Gomes C., Cunha C., Nascimento F., Ribeiro J.A., Vaz A.R., Brites D. Cortical Neurotoxic Astrocytes with Early ALS Pathology and miR-146a Deficit Replicate Gliosis Markers of Symptomatic SOD1G93A Mouse Model. Mol. Neurobiol. 2019;56:2137–2158. doi: 10.1007/s12035-018-1220-8. PubMed DOI

Zamanian J.L., Xu L., Foo L.C., Nouri N., Zhou L., Giffard R.G., Barres B.A. Genomic analysis of reactive astrogliosis. J. Neurosci. 2012;32:6391–6410. doi: 10.1523/JNEUROSCI.6221-11.2012. PubMed DOI PMC

Faulkner J.R., Herrmann J.E., Woo M.J., Tansey K.E., Doan N.B., Sofroniew M.V. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 2004;24:2143–2155. doi: 10.1523/JNEUROSCI.3547-03.2004. PubMed DOI PMC

Haidet-Phillips A.M., Hester M.E., Miranda C.J., Meyer K., Braun L., Frakes A., Song S., Likhite S., Murtha M.J., Foust K.D., et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824–828. doi: 10.1038/nbt.1957. PubMed DOI PMC

Diaz-Amarilla P., Olivera-Bravo S., Trias E., Cragnolini A., Martinez-Palma L., Cassina P., Beckman J., Barbeito L. Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2011;108:18126–18131. doi: 10.1073/pnas.1110689108. PubMed DOI PMC

Theodoric N., Bechberger J.F., Naus C.C., Sin W.C. Role of gap junction protein connexin43 in astrogliosis induced by brain injury. PLoS ONE. 2012;7:e47311. doi: 10.1371/journal.pone.0047311. PubMed DOI PMC

Almad A.A., Doreswamy A., Gross S.K., Richard J.P., Huo Y., Haughey N., Maragakis N.J. Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia. 2016;64:1154–1169. doi: 10.1002/glia.22989. PubMed DOI PMC

Gallardo G., Barowski J., Ravits J., Siddique T., Lingrel J.B., Robertson J., Steen H., Bonni A. An alpha2-Na/K ATPase/alpha-adducin complex in astrocytes triggers non-cell autonomous neurodegeneration. Nat. Neurosci. 2014;17:1710–1719. doi: 10.1038/nn.3853. PubMed DOI PMC

Rose E.M., Koo J.C., Antflick J.E., Ahmed S.M., Angers S., Hampson D.R. Glutamate transporter coupling to Na,K-ATPase. J. Neurosci. 2009;29:8143–8155. doi: 10.1523/JNEUROSCI.1081-09.2009. PubMed DOI PMC

Illarionova N.B., Brismar H., Aperia A., Gunnarson E. Role of Na,K-ATPase alpha1 and alpha2 isoforms in the support of astrocyte glutamate uptake. PLoS ONE. 2014;9:e98469. doi: 10.1371/journal.pone.0098469. PubMed DOI PMC

Tyzack G.E., Hall C.E., Sibley C.R., Cymes T., Forostyak S., Carlino G., Meyer I.F., Schiavo G., Zhang S.C., Gibbons G.M., et al. A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models. Nat. Commun. 2017;8:1164. doi: 10.1038/s41467-017-01283-z. PubMed DOI PMC

Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615–622. doi: 10.1038/nn1876. PubMed DOI PMC

Di Giorgio F.P., Carrasco M.A., Siao M.C., Maniatis T., Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 2007;10:608–614. doi: 10.1038/nn1885. PubMed DOI PMC

Marchetto M.C., Muotri A.R., Mu Y., Smith A.M., Cezar G.G., Gage F.H. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3:649–657. doi: 10.1016/j.stem.2008.10.001. PubMed DOI

Meyer K., Ferraiuolo L., Miranda C.J., Likhite S., McElroy S., Renusch S., Ditsworth D., Lagier-Tourenne C., Smith R.A., Ravits J., et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc. Natl. Acad. Sci. USA. 2014;111:829–832. doi: 10.1073/pnas.1314085111. PubMed DOI PMC

Tripathi P., Rodriguez-Muela N., Klim J.R., de Boer A.S., Agrawal S., Sandoe J., Lopes C.S., Ogliari K.S., Williams L.A., Shear M., et al. Reactive Astrocytes Promote ALS-like Degeneration and Intracellular Protein Aggregation in Human Motor Neurons by Disrupting Autophagy through TGF-beta1. Stem Cell Rep. 2017;9:667–680. doi: 10.1016/j.stemcr.2017.06.008. PubMed DOI PMC

Rojas F., Cortes N., Abarzua S., Dyrda A., van Zundert B. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front. Cell. Neurosci. 2014;8:24. doi: 10.3389/fncel.2014.00024. PubMed DOI PMC

Di Giorgio F.P., Boulting G.L., Bobrowicz S., Eggan K.C. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell. 2008;3:637–648. doi: 10.1016/j.stem.2008.09.017. PubMed DOI

Huang C., Huang B., Bi F., Yan L.H., Tong J., Huang J., Xia X.G., Zhou H. Profiling the genes affected by pathogenic TDP-43 in astrocytes. J. Neurochem. 2014;129:932–939. doi: 10.1111/jnc.12660. PubMed DOI PMC

Kia A., McAvoy K., Krishnamurthy K., Trotti D., Pasinelli P. Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha. Glia. 2018;66:1016–1033. doi: 10.1002/glia.23298. PubMed DOI PMC

Shi P., Gal J., Kwinter D.M., Liu X., Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim. Biophys. Acta. 2010;1802:45–51. doi: 10.1016/j.bbadis.2009.08.012. PubMed DOI PMC

Madill M., McDonagh K., Ma J., Vajda A., McLoughlin P., O’Brien T., Hardiman O., Shen S. Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Mol. Brain. 2017;10:22. doi: 10.1186/s13041-017-0300-4. PubMed DOI PMC

Re D.B., Le Verche V., Yu C., Amoroso M.W., Politi K.A., Phani S., Ikiz B., Hoffmann L., Koolen M., Nagata T., et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014;81:1001–1008. doi: 10.1016/j.neuron.2014.01.011. PubMed DOI PMC

Ouali Alami N., Schurr C., Olde Heuvel F., Tang L., Li Q., Tasdogan A., Kimbara A., Nettekoven M., Ottaviani G., Raposo C., et al. NF-kappaB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. EMBO J. 2018;37 doi: 10.15252/embj.201798697. PubMed DOI PMC

Conlon E.G., Lu L., Sharma A., Yamazaki T., Tang T., Shneider N.A., Manley J.L. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. Elife. 2016;5 doi: 10.7554/eLife.17820. PubMed DOI PMC

Kanekura K., Yagi T., Cammack A.J., Mahadevan J., Kuroda M., Harms M.B., Miller T.M., Urano F. Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Hum. Mol. Genet. 2016;25:1803–1813. doi: 10.1093/hmg/ddw052. PubMed DOI PMC

Hautbergue G.M., Castelli L.M., Ferraiuolo L., Sanchez-Martinez A., Cooper-Knock J., Higginbottom A., Lin Y.H., Bauer C.S., Dodd J.E., Myszczynska M.A., et al. SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nat. Commun. 2017;8:16063. doi: 10.1038/ncomms16063. PubMed DOI PMC

Gupta R., Lan M., Mojsilovic-Petrovic J., Choi W.H., Safren N., Barmada S., Lee M.J., Kalb R. The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded C9ORF72 Inhibits the Proteasome. eNeuro. 2017;4 doi: 10.1523/ENEURO.0249-16.2017. PubMed DOI PMC

Mordes D.A., Prudencio M., Goodman L.D., Klim J.R., Moccia R., Limone F., Pietilainen O., Chowdhary K., Dickson D.W., Rademakers R., et al. Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients. Acta Neuropathol. Commun. 2018;6:55. doi: 10.1186/s40478-018-0555-8. PubMed DOI PMC

Allen S.P., Hall B., Castelli L.M., Francis L., Woof R., Siskos A.P., Kouloura E., Gray E., Thompson A.G., Talbot K., et al. Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain. 2019;142:586–605. doi: 10.1093/brain/awy353. PubMed DOI PMC

Fomin V., Richard P., Hoque M., Li C., Gu Z., Fissore-O’Leary M., Tian B., Prives C., Manley J.L. The C9ORF72 Gene, Implicated in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, Encodes a Protein That Functions in Control of Endothelin and Glutamate Signaling. Mol. Cell. Biol. 2018;38:e00155-18. doi: 10.1128/MCB.00155-18. PubMed DOI PMC

Diaper D.C., Adachi Y., Lazarou L., Greenstein M., Simoes F.A., Di Domenico A., Solomon D.A., Lowe S., Alsubaie R., Cheng D., et al. Drosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLD. Hum. Mol. Genet. 2013;22:3883–3893. doi: 10.1093/hmg/ddt243. PubMed DOI PMC

Zhao C., Devlin A.C., Chouhan A.K., Selvaraj B.T., Stavrou M., Burr K., Brivio V., He X., Mehta A.R., Story D., et al. Mutant C9orf72 human iPSC-derived astrocytes cause non-cell autonomous motor neuron pathophysiology. Glia. 2019 doi: 10.1002/glia.23761. PubMed DOI PMC

Birger A., Ben-Dor I., Ottolenghi M., Turetsky T., Gil Y., Sweetat S., Perez L., Belzer V., Casden N., Steiner D., et al. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. EBioMedicine. 2019;50:274–289. doi: 10.1016/j.ebiom.2019.11.026. PubMed DOI PMC

Varcianna A., Myszczynska M.A., Castelli L.M., O’Neill B., Kim Y., Talbot J., Nyberg S., Nyamali I., Heath P.R., Stopford M.J., et al. Micro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS. EBioMedicine. 2019;40:626–635. doi: 10.1016/j.ebiom.2018.11.067. PubMed DOI PMC

Ishii T., Kawakami E., Endo K., Misawa H., Watabe K. Formation and spreading of TDP-43 aggregates in cultured neuronal and glial cells demonstrated by time-lapse imaging. PLoS ONE. 2017;12:e0179375. doi: 10.1371/journal.pone.0179375. PubMed DOI PMC

Haidet-Phillips A.M., Gross S.K., Williams T., Tuteja A., Sherman A., Ko M., Jeong Y.H., Wong P.C., Maragakis N.J. Altered astrocytic expression of TDP-43 does not influence motor neuron survival. Exp. Neurol. 2013;250:250–259. doi: 10.1016/j.expneurol.2013.10.004. PubMed DOI

Serio A., Bilican B., Barmada S.J., Ando D.M., Zhao C., Siller R., Burr K., Haghi G., Story D., Nishimura A.L., et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc. Natl. Acad. Sci. USA. 2013;110:4697–4702. doi: 10.1073/pnas.1300398110. PubMed DOI PMC

Khalfallah Y., Kuta R., Grasmuck C., Prat A., Durham H.D., Vande Velde C. TDP-43 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types. Sci. Rep. 2018;8:7551. doi: 10.1038/s41598-018-25767-0. PubMed DOI PMC

Koga S., Lin W.L., Walton R.L., Ross O.A., Dickson D.W. TDP-43 pathology in multiple system atrophy: Colocalization of TDP-43 and alpha-synuclein in glial cytoplasmic inclusions. Neuropathol. Appl. Neurobiol. 2018;44:707–721. doi: 10.1111/nan.12485. PubMed DOI PMC

Mackenzie I.R., Nicholson A.M., Sarkar M., Messing J., Purice M.D., Pottier C., Annu K., Baker M., Perkerson R.B., Kurti A., et al. TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron. 2017;95:808–816.e9. doi: 10.1016/j.neuron.2017.07.025. PubMed DOI PMC

Jeon G.S., Shim Y.M., Lee D.Y., Kim J.S., Kang M., Ahn S.H., Shin J.Y., Geum D., Hong Y.H., Sung J.J. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations. Mol. Neurobiol. 2019;56:2007–2021. doi: 10.1007/s12035-018-1218-2. PubMed DOI PMC

Estes P.S., Daniel S.G., McCallum A.P., Boehringer A.V., Sukhina A.S., Zwick R.A., Zarnescu D.C. Motor neurons and glia exhibit specific individualized responses to TDP-43 expression in a Drosophila model of amyotrophic lateral sclerosis. Dis. Model. Mech. 2013;6:721–733. doi: 10.1242/dmm.010710. PubMed DOI PMC

Moujalled D., Grubman A., Acevedo K., Yang S., Ke Y.D., Moujalled D.M., Duncan C., Caragounis A., Perera N.D., Turner B.J., et al. TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Hum. Mol. Genet. 2017;26:1732–1746. doi: 10.1093/hmg/ddx093. PubMed DOI

Ke Y.D., van Hummel A., Stevens C.H., Gladbach A., Ippati S., Bi M., Lee W.S., Kruger S., van der Hoven J., Volkerling A., et al. Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol. 2015;130:661–678. doi: 10.1007/s00401-015-1486-0. PubMed DOI

LaRocca T.J., Mariani A., Watkins L.R., Link C.D. TDP-43 knockdown causes innate immune activation via protein kinase R in astrocytes. Neurobiol. Dis. 2019;132:104514. doi: 10.1016/j.nbd.2019.104514. PubMed DOI PMC

Lee J.D., Levin S.C., Willis E.F., Li R., Woodruff T.M., Noakes P.G. Complement components are upregulated and correlate with disease progression in the TDP-43(Q331K) mouse model of amyotrophic lateral sclerosis. J. Neuroinflamm. 2018;15:171. doi: 10.1186/s12974-018-1217-2. PubMed DOI PMC

Jara J.H., Gautam M., Kocak N., Xie E.F., Mao Q., Bigio E.H., Ozdinler P.H. MCP1-CCR2 and neuroinflammation in the ALS motor cortex with TDP-43 pathology. J. Neuroinflamm. 2019;16:196. doi: 10.1186/s12974-019-1589-y. PubMed DOI PMC

Gorter R.P., Stephenson J., Nutma E., Anink J., de Jonge J.C., Baron W., Jahreibeta M.C., Belien J.A.M., van Noort J.M., Mijnsbergen C., et al. Rapidly progressive amyotrophic lateral sclerosis is associated with microglial reactivity and small heat shock protein expression in reactive astrocytes. Neuropathol. Appl. Neurobiol. 2019;45:459–475. doi: 10.1111/nan.12525. PubMed DOI PMC

Webster J.M., Darling A.L., Uversky V.N., Blair L.J. Small Heat Shock Proteins, Big Impact on Protein Aggregation in Neurodegenerative Disease. Front. Pharmacol. 2019;10:1047. doi: 10.3389/fphar.2019.01047. PubMed DOI PMC

Romano G., Appocher C., Scorzeto M., Klima R., Baralle F.E., Megighian A., Feiguin F. Glial TDP-43 regulates axon wrapping, GluRIIA clustering and fly motility by autonomous and non-autonomous mechanisms. Hum. Mol. Genet. 2015;24:6134–6145. doi: 10.1093/hmg/ddv330. PubMed DOI PMC

Corcia P., Tauber C., Vercoullie J., Arlicot N., Prunier C., Praline J., Nicolas G., Venel Y., Hommet C., Baulieu J.L., et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e52941. doi: 10.1371/journal.pone.0052941. PubMed DOI PMC

Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C.J., Shaw C.E., Brooks D.J., Leigh P.N., Banati R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004;15:601–609. doi: 10.1016/j.nbd.2003.12.012. PubMed DOI

Chiu I.M., Morimoto E.T., Goodarzi H., Liao J.T., O’Keeffe S., Phatnani H.P., Muratet M., Carroll M.C., Levy S., Tavazoie S., et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4:385–401. doi: 10.1016/j.celrep.2013.06.018. PubMed DOI PMC

Liao B., Zhao W., Beers D.R., Henkel J.S., Appel S.H. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 2012;237:147–152. doi: 10.1016/j.expneurol.2012.06.011. PubMed DOI PMC

Ohgomori T., Yamada J., Takeuchi H., Kadomatsu K., Jinno S. Comparative morphometric analysis of microglia in the spinal cord of SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 2016;43:1340–1351. doi: 10.1111/ejn.13227. PubMed DOI

Gravel M., Béland L.C., Soucy G., Abdelhamid E., Rahimian R., Gravel C., Kriz J. IL-10 Controls Early Microglial Phenotypes and Disease Onset in ALS Caused by Misfolded Superoxide Dismutase 1. J. Neurosci. 2016;36:1031–1048. doi: 10.1523/JNEUROSCI.0854-15.2016. PubMed DOI PMC

Beers D.R., Henkel J.S., Zhao W., Wang J., Huang A., Wen S., Liao B., Appel S.H. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293–1314. doi: 10.1093/brain/awr074. PubMed DOI PMC

Ito Y., Yamada M., Tanaka H., Aida K., Tsuruma K., Shimazawa M., Hozumi I., Inuzuka T., Takahashi H., Hara H. Involvement of CHOP, an ER-stress apoptotic mediator, in both human sporadic ALS and ALS model mice. Neurobiol. Dis. 2009;36:470–476. doi: 10.1016/j.nbd.2009.08.013. PubMed DOI

D’Ambrosi N., Finocchi P., Apolloni S., Cozzolino M., Ferri A., Padovano V., Pietrini G., Carrì M.T., Volonté C. The Proinflammatory Action of Microglial P2 Receptors Is Enhanced in SOD1 Models for Amyotrophic Lateral Sclerosis. J. Immunol. 2009;183:4648–4656. doi: 10.4049/jimmunol.0901212. PubMed DOI

Frakes A.E., Ferraiuolo L., Haidet-Phillips A.M., Schmelzer L., Braun L., Miranda C.J., Ladner K.J., Bevan A.K., Foust K.D., Godbout J.P., et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009–1023. doi: 10.1016/j.neuron.2014.01.013. PubMed DOI PMC

Harraz M.M., Marden J.J., Zhou W., Zhang Y., Williams A., Sharov V.S., Nelson K., Luo M., Paulson H., Schöneich C., et al. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J. Clin. Investig. 2008;118:659–670. doi: 10.1172/JCI34060. PubMed DOI PMC

Burberry A., Suzuki N., Wang J.Y., Moccia R., Mordes D.A., Stewart M.H., Suzuki-Uematsu S., Ghosh S., Singh A., Merkle F.T., et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med. 2016;8:347ra393. doi: 10.1126/scitranslmed.aaf6038. PubMed DOI PMC

Rudnick N.D., Griffey C.J., Guarnieri P., Gerbino V., Wang X., Piersaint J.A., Tapia J.C., Rich M.M., Maniatis T. Distinct roles for motor neuron autophagy early and late in the SOD1(G93A) mouse model of ALS. Proc. Natl. Acad. Sci. USA. 2017;114:E8294–E8303. doi: 10.1073/pnas.1704294114. PubMed DOI PMC

Strohm L., Behrends C. Glia-specific autophagy dysfunction in ALS. Semin. Cell Dev. Biol. 2019 doi: 10.1016/j.semcdb.2019.05.024. PubMed DOI

Barmada S.J., Skibinski G., Korb E., Rao E.J., Wu J.Y., Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. Off. J. Soc. Neurosci. 2010;30:639–649. doi: 10.1523/JNEUROSCI.4988-09.2010. PubMed DOI PMC

Codolo G., Plotegher N., Pozzobon T., Brucale M., Tessari I., Bubacco L., de Bernard M. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS ONE. 2013;8:e55375. doi: 10.1371/journal.pone.0055375. PubMed DOI PMC

Gordon R., Albornoz E.A., Christie D.C., Langley M.R., Kumar V., Mantovani S., Robertson A.A.B., Butler M.S., Rowe D.B., O’Neill L.A., et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med. 2018;10:eaah4066. doi: 10.1126/scitranslmed.aah4066. PubMed DOI PMC

Heneka M.T., Kummer M.P., Stutz A., Delekate A., Schwartz S., Vieira-Saecker A., Griep A., Axt D., Remus A., Tzeng T.-C., et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674–678. doi: 10.1038/nature11729. PubMed DOI PMC

Parajuli B., Sonobe Y., Horiuchi H., Takeuchi H., Mizuno T., Suzumura A. Oligomeric amyloid β induces IL-1β processing via production of ROS: Implication in Alzheimer’s disease. Cell Death Dis. 2013;4:e975. doi: 10.1038/cddis.2013.503. PubMed DOI PMC

Patel M.N., Carroll R.G., Galvan-Pena S., Mills E.L., Olden R., Triantafilou M., Wolf A.I., Bryant C.E., Triantafilou K., Masters S.L. Inflammasome Priming in Sterile Inflammatory Disease. Trends Mol. Med. 2017;23:165–180. doi: 10.1016/j.molmed.2016.12.007. PubMed DOI

Deora V., Lee J.D., Albornoz E.A., McAlary L., Jagaraj C.J., Robertson A.A.B., Atkin J.D., Cooper M.A., Schroder K., Yerbury J.J., et al. The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia. 2019 doi: 10.1002/glia.23728. PubMed DOI

Zhao W., Beers D.R., Bell S., Wang J., Wen S., Baloh R.H., Appel S.H. TDP-43 activates microglia through NF-kappaB and NLRP3 inflammasome. Exp. Neurol. 2015;273:24–35. doi: 10.1016/j.expneurol.2015.07.019. PubMed DOI

Zhao W., Beers D.R., Henkel J.S., Zhang W., Urushitani M., Julien J.-P., Appel S.H. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia. 2010;58:231–243. doi: 10.1002/glia.20919. PubMed DOI PMC

Spiller K.J., Restrepo C.R., Khan T., Dominique M.A., Fang T.C., Canter R.G., Roberts C.J., Miller K.R., Ransohoff R.M., Trojanowski J.Q., et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat. Neurosci. 2018;21:329–340. doi: 10.1038/s41593-018-0083-7. PubMed DOI PMC

Granucci E.J., Griciuc A., Mueller K.A., Mills A.N., Le H., Dios A.M., McGinty D., Pereira J., Elmaleh D., Berry J.D., et al. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1(G93A) Mouse Model of amyotrophic lateral sclerosis. Sci. Rep. 2019;9:17728. doi: 10.1038/s41598-019-53982-w. PubMed DOI PMC

Zhou Q., Mareljic N., Michaelsen M., Parhizkar S., Heindl S., Nuscher B., Farny D., Czuppa M., Schludi C., Graf A., et al. Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. EMBO Mol. Med. 2019:e10919. doi: 10.15252/emmm.201910919. PubMed DOI PMC

Zhu X., Bergles D.E., Nishiyama A. NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development. 2008;135:145–157. doi: 10.1242/dev.004895. PubMed DOI

Guo F., Ma J., McCauley E., Bannerman P., Pleasure D. Early Postnatal Proteolipid Promoter-Expressing Progenitors Produce Multilineage Cells In Vivo. J. Neurosci. 2009;29:7256–7270. doi: 10.1523/JNEUROSCI.5653-08.2009. PubMed DOI PMC

Rivers L.E., Young K.M., Rizzi M., Jamen F., Psachoulia K., Wade A., Kessaris N., Richardson W.D. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat. Neurosci. 2008;11:1392–1401. doi: 10.1038/nn.2220. PubMed DOI PMC

Aguirre A.A., Chittajallu R., Belachew S., Gallo V. NG2-expressing cells in the subventricular zone are type C-like cells and contribute to interneuron generation in the postnatal hippocampus. J. Cell Biol. 2004;165:575–589. doi: 10.1083/jcb.200311141. PubMed DOI PMC

Kang S.H., Fukaya M., Yang J.K., Rothstein J.D., Bergles D.E. NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron. 2010;68:668–681. doi: 10.1016/j.neuron.2010.09.009. PubMed DOI PMC

Wang J., Ho W.Y., Lim K., Feng J., Tucker-Kellogg G., Nave K.A., Ling S.C. Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination. Proc. Natl. Acad. Sci. USA. 2018;115:E10941–E10950. doi: 10.1073/pnas.1809821115. PubMed DOI PMC

Hartline D.K., Colman D.R. Rapid Conduction and the Evolution of Giant Axons and Myelinated Fibers. Curr. Biol. 2007;17:R29–R35. doi: 10.1016/j.cub.2006.11.042. PubMed DOI

Lee Y., Morrison B.M., Li Y., Lengacher S., Farah M.H., Hoffman P.N., Liu Y., Tsingalia A., Jin L., Zhang P.W., et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487:443–448. doi: 10.1038/nature11314. PubMed DOI PMC

Fünfschilling U., Supplie L.M., Mahad D., Boretius S., Saab A.S., Edgar J., Brinkmann B.G., Kassmann C.M., Tzvetanova I.D., Möbius W., et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485:517–521. doi: 10.1038/nature11007. PubMed DOI PMC

Saab A.S., Tzvetavona I.D., Trevisiol A., Baltan S., Dibaj P., Kusch K., Mobius W., Goetze B., Jahn H.M., Huang W., et al. Oligodendroglial NMDA Receptors Regulate Glucose Import and Axonal Energy Metabolism. Neuron. 2016;91:119–132. doi: 10.1016/j.neuron.2016.05.016. PubMed DOI PMC

Philips T., Bento-Abreu A., Nonneman A., Haeck W., Staats K., Geelen V., Hersmus N., Küsters B., Van Den Bosch L., Van Damme P., et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain A J. Neurol. 2013;136:471–482. doi: 10.1093/brain/aws339. PubMed DOI PMC

Yamanaka K., Boillee S., Roberts E.A., Garcia M.L., McAlonis-Downes M., Mikse O.R., Cleveland D.W., Goldstein L.S. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc. Natl. Acad. Sci. USA. 2008;105:7594–7599. doi: 10.1073/pnas.0802556105. PubMed DOI PMC

Ferraiuolo L., Meyer K., Sherwood T.W., Vick J., Likhite S., Frakes A., Miranda C.J., Braun L., Heath P.R., Pineda R., et al. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc. Natl. Acad. Sci. USA. 2016;113:E6496–E6505. doi: 10.1073/pnas.1607496113. PubMed DOI PMC

Kim S., Chung A.Y., Na J.E., Lee S.J., Jeong S.H., Kim E., Sun W., Rhyu I.J., Park H.C. Myelin degeneration induced by mutant superoxide dismutase 1 accumulation promotes amyotrophic lateral sclerosis. Glia. 2019;67:1910–1921. doi: 10.1002/glia.23669. PubMed DOI

Pieri M., Carunchio I., Curcio L., Mercuri N.B., Zona C. Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp. Neurol. 2009;215:368–379. doi: 10.1016/j.expneurol.2008.11.002. PubMed DOI

Vucic S., Cheah B.C., Yiannikas C., Kiernan M.C. Cortical excitability distinguishes ALS from mimic disorders. Clin. Neurophysiol. 2011;122:1860–1866. doi: 10.1016/j.clinph.2010.12.062. PubMed DOI

Vucic S., Nicholson G.A., Kiernan M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131:1540–1550. doi: 10.1093/brain/awn071. PubMed DOI

Marcuzzo S., Terragni B., Bonanno S., Isaia D., Cavalcante P., Cappelletti C., Ciusani E., Rizzo A., Regalia G., Yoshimura N., et al. Hyperexcitability in Cultured Cortical Neuron Networks from the G93A-SOD1 Amyotrophic Lateral Sclerosis Model Mouse and its Molecular Correlates. Neuroscience. 2019;416:88–99. doi: 10.1016/j.neuroscience.2019.07.041. PubMed DOI

Mackenzie I.R.A., Ansorge O., Strong M., Bilbao J., Zinman L., Ang L.-C., Baker M., Stewart H., Eisen A., Rademakers R., et al. Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: Two distinct patterns correlating with disease severity and mutation. Acta Neuropathol. 2011;122:87–98. doi: 10.1007/s00401-011-0838-7. PubMed DOI PMC

Netto J.P., Iliff J., Stanimirovic D., Krohn K.A., Hamilton B., Varallyay C., Gahramanov S., Daldrup-Link H., d’Esterre C., Zlokovic B., et al. Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol. Neurosurgery. 2018;82:770–780. doi: 10.1093/neuros/nyx357. PubMed DOI PMC

Krueger M., Bechmann I. CNS pericytes: Concepts, misconceptions, and a way out. Glia. 2010;58:1–10. doi: 10.1002/glia.20898. PubMed DOI

Armulik A., Genove G., Betsholtz C. Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell. 2011;21:193–215. doi: 10.1016/j.devcel.2011.07.001. PubMed DOI

Cheng J., Korte N., Nortley R., Sethi H., Tang Y., Attwell D. Targeting pericytes for therapeutic approaches to neurological disorders. Acta Neuropathol. 2018;136:507–523. doi: 10.1007/s00401-018-1893-0. PubMed DOI PMC

Hall C.N., Reynell C., Gesslein B., Hamilton N.B., Mishra A., Sutherland B.A., O’Farrell F.M., Buchan A.M., Lauritzen M., Attwell D. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508:55–60. doi: 10.1038/nature13165. PubMed DOI PMC

Sweeney M.D., Ayyadurai S., Zlokovic B.V. Pericytes of the neurovascular unit: Key functions and signaling pathways. Nat. Neurosci. 2016;19:771–783. doi: 10.1038/nn.4288. PubMed DOI PMC

Bell R.D., Winkler E.A., Sagare A.P., Singh I., LaRue B., Deane R., Zlokovic B.V. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409–427. doi: 10.1016/j.neuron.2010.09.043. PubMed DOI PMC

Daneman R., Zhou L., Kebede A.A., Barres B.A. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468:562–566. doi: 10.1038/nature09513. PubMed DOI PMC

Rustenhoven J., Jansson D., Smyth L.C., Dragunow M. Brain Pericytes As Mediators of Neuroinflammation. Trends Pharmacol. Sci. 2017;38:291–304. doi: 10.1016/j.tips.2016.12.001. PubMed DOI

Dias D.O., Kim H., Holl D., Werne Solnestam B., Lundeberg J., Carlen M., Goritz C., Frisen J. Reducing Pericyte-Derived Scarring Promotes Recovery after Spinal Cord Injury. Cell. 2018;173:153–165.e22. doi: 10.1016/j.cell.2018.02.004. PubMed DOI PMC

Hesp Z.C., Yoseph R.Y., Suzuki R., Jukkola P., Wilson C., Nishiyama A., McTigue D.M. Proliferating NG2-Cell-Dependent Angiogenesis and Scar Formation Alter Axon Growth and Functional Recovery After Spinal Cord Injury in Mice. J. Neurosci. 2018;38:1366–1382. doi: 10.1523/JNEUROSCI.3953-16.2017. PubMed DOI PMC

Apostolski S., Nikolic J., Bugarski-Prokopljevic C., Miletic V., Pavlovic S., Filipovic S. Serum and CSF immunological findings in ALS. Acta Neurol. Scand. 1991;83:96–98. doi: 10.1111/j.1600-0404.1991.tb04656.x. PubMed DOI

Meucci G., Rossi G., Bettini R., Montanaro D., Gironelli L., Voci L., Bianchi F. Laser nephelometric evaluation of albumin, IgG and alpha 2-macroglobulin: Applications to the study of alterations of the blood-brain barrier. J. Neurol. Sci. 1993;118:73–78. doi: 10.1016/0022-510X(93)90248-W. PubMed DOI

Engelhardt J.I., Tajti J., Appel S.H. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 1993;50:30–36. doi: 10.1001/archneur.1993.00540010026013. PubMed DOI

Henkel J.S., Beers D.R., Wen S., Bowser R., Appel S.H. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology. 2009;72:1614–1616. doi: 10.1212/WNL.0b013e3181a41228. PubMed DOI

Garbuzova-Davis S., Hernandez-Ontiveros D.G., Rodrigues M.C., Haller E., Frisina-Deyo A., Mirtyl S., Sallot S., Saporta S., Borlongan C.V., Sanberg P.R. Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114–128. doi: 10.1016/j.brainres.2012.05.056. PubMed DOI

Miyazaki K., Ohta Y., Nagai M., Morimoto N., Kurata T., Takehisa Y., Ikeda Y., Matsuura T., Abe K. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J. Neurosci. Res. 2011;89:718–728. doi: 10.1002/jnr.22594. PubMed DOI

Nicaise C., Mitrecic D., Demetter P., De Decker R., Authelet M., Boom A., Pochet R. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 2009;1301:152–162. doi: 10.1016/j.brainres.2009.09.018. PubMed DOI

Zhong Z., Deane R., Ali Z., Parisi M., Shapovalov Y., O’Banion M.K., Stojanovic K., Sagare A., Boillee S., Cleveland D.W., et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 2008;11:420–422. doi: 10.1038/nn2073. PubMed DOI PMC

Lobsiger C.S., Boillee S., Cleveland D.W. Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc. Natl. Acad. Sci. USA. 2007;104:7319–7326. doi: 10.1073/pnas.0702230104. PubMed DOI PMC

Winkler E.A., Sengillo J.D., Sullivan J.S., Henkel J.S., Appel S.H., Zlokovic B.V. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:111–120. doi: 10.1007/s00401-012-1039-8. PubMed DOI PMC

Sasaki S. Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis. Neuropathology. 2015;35:518–528. doi: 10.1111/neup.12221. PubMed DOI

Sasaki S., Iguchi Y., Katsuno M., Sobue G. Alterations in the blood-spinal cord barrier in TDP-43 conditional knockout mice. Neurosci. Lett. 2015;598:1–5. doi: 10.1016/j.neulet.2015.05.005. PubMed DOI

Coatti G.C., Frangini M., Valadares M.C., Gomes J.P., Lima N.O., Cavacana N., Assoni A.F., Pelatti M.V., Birbrair A., de Lima A.C.P., et al. Pericytes Extend Survival of ALS SOD1 Mice and Induce the Expression of Antioxidant Enzymes in the Murine Model and in IPSCs Derived Neuronal Cells from an ALS Patient. Stem Cell Rev. Rep. 2017;13:686–698. doi: 10.1007/s12015-017-9752-2. PubMed DOI

Wang L., Gutmann D.H., Roos R.P. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 2011;20:286–293. doi: 10.1093/hmg/ddq463. PubMed DOI

Endo F., Komine O., Fujimori-Tonou N., Katsuno M., Jin S., Watanabe S., Sobue G., Dezawa M., Wyss-Coray T., Yamanaka K. Astrocyte-derived TGF-beta1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 2015;11:592–604. doi: 10.1016/j.celrep.2015.03.053. PubMed DOI

Franklin R.J.M., Goldman S.A. Glia Disease and Repair-Remyelination. Cold Spring Harb. Perspect. Biol. 2015;7:a020594. doi: 10.1101/cshperspect.a020594. PubMed DOI PMC

Talbott J.F., Loy D.N., Liu Y., Qiu M.S., Bunge M.B., Rao M.S., Whittemore S.R. Endogenous Nkx2.2+/Olig2+ oligodendrocyte precursor cells fail to remyelinate the demyelinated adult rat spinal cord in the absence of astrocytes. Exp. Neurol. 2005;192:11–24. doi: 10.1016/j.expneurol.2004.05.038. PubMed DOI PMC

Lapucci A., Cavone L., Buonvicino D., Felici R., Gerace E., Zwergel C., Valente S., Mai A., Chiarugi A. Effect of Class II HDAC inhibition on glutamate transporter expression and survival in SOD1-ALS mice. Neurosci. Lett. 2017;656:120–125. doi: 10.1016/j.neulet.2017.07.033. PubMed DOI

Fischer A., Sananbenesi F., Mungenast A., Tsai L.H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 2010;31:605–617. doi: 10.1016/j.tips.2010.09.003. PubMed DOI

Kong Q., Chang L.C., Takahashi K., Liu Q., Schulte D.A., Lai L., Ibabao B., Lin Y., Stouffer N., Das Mukhopadhyay C., et al. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J. Clin. Investig. 2014;124:1255–1267. doi: 10.1172/JCI66163. PubMed DOI PMC

Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73–77. doi: 10.1038/nature03180. PubMed DOI

Rothstein J.D., Jin L., Dykes-Hoberg M., Kuncl R.W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA. 1993;90:6591–6595. doi: 10.1073/pnas.90.14.6591. PubMed DOI PMC

Berry J.D., Shefner J.M., Conwit R., Schoenfeld D., Keroack M., Felsenstein D., Krivickas L., David W.S., Vriesendorp F., Pestronk A., et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS ONE. 2013;8:e61177. doi: 10.1371/journal.pone.0061177. PubMed DOI PMC

Cudkowicz M.E., Titus S., Kearney M., Yu H., Sherman A., Schoenfeld D., Hayden D., Shui A., Brooks B., Conwit R., et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083–1091. doi: 10.1016/S1474-4422(14)70222-4. PubMed DOI PMC

Ganel R., Ho T., Maragakis N.J., Jackson M., Steiner J.P., Rothstein J.D. Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection. Neurobiol. Dis. 2006;21:556–567. doi: 10.1016/j.nbd.2005.08.014. PubMed DOI

Lyons W.E., George E.B., Dawson T.M., Steiner J.P., Snyder S.H. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc. Natl. Acad. Sci. USA. 1994;91:3191–3195. doi: 10.1073/pnas.91.8.3191. PubMed DOI PMC

Steiner J.P., Connolly M.A., Valentine H.L., Hamilton G.S., Dawson T.M., Hester L., Snyder S.H. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat. Med. 1997;3:421–428. doi: 10.1038/nm0497-421. PubMed DOI

Winter A.N., Ross E.K., Wilkins H.M., Stankiewicz T.R., Wallace T., Miller K., Linseman D.A. An anthocyanin-enriched extract from strawberries delays disease onset and extends survival in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. Nutr. Neurosci. 2018;21:414–426. doi: 10.1080/1028415X.2017.1297023. PubMed DOI

Tanaka K., Kanno T., Yanagisawa Y., Yasutake K., Hadano S., Yoshii F., Ikeda J.E. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2011;232:41–52. doi: 10.1016/j.expneurol.2011.08.001. PubMed DOI

Rodriguez-Cueto C., Santos-Garcia I., Garcia-Toscano L., Espejo-Porras F., Bellido M., Fernandez-Ruiz J., Munoz E., de Lago E. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1(G93A) transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochem. Pharmacol. 2018;157:217–226. doi: 10.1016/j.bcp.2018.07.049. PubMed DOI

Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O’Rahilly S., et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006;58:726–741. doi: 10.1124/pr.58.4.5. PubMed DOI

Rabinovich-Nikitin I., Ezra A., Barbiro B., Rabinovich-Toidman P., Solomon B. Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1(G93A) mice model of ALS. J. Neuroinflamm. 2016;13:123. doi: 10.1186/s12974-016-0587-6. PubMed DOI PMC

Martinez-Muriana A., Mancuso R., Francos-Quijorna I., Olmos-Alonso A., Osta R., Perry V.H., Navarro X., Gomez-Nicola D., Lopez-Vales R. CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves. Sci. Rep. 2016;6:25663. doi: 10.1038/srep25663. PubMed DOI PMC

Hu H., Lin H., Duan W., Cui C., Li Z., Liu Y., Wang W., Wen D., Wang Y., Li C. Intrathecal Injection of scAAV9-hIGF1 Prolongs the Survival of ALS Model Mice by Inhibiting the NF-kB Pathway. Neuroscience. 2018;381:1–10. doi: 10.1016/j.neuroscience.2018.02.004. PubMed DOI

Edwards J.N., Macdonald W.A., van der Poel C., Stephenson D.G. O2(*-) production at 37 degrees C plays a critical role in depressing tetanic force of isolated rat and mouse skeletal muscle. Am. J. Physiol. Cell Physiol. 2007;293:C650–C660. doi: 10.1152/ajpcell.00037.2007. PubMed DOI

Burns D.P., Ali I., Rieux C., Healy J., Jasionek G., O’Halloran K.D. Tempol Supplementation Restores Diaphragm Force and Metabolic Enzyme Activities in mdx Mice. Antioxid. (Basel) 2017;6 doi: 10.3390/antiox6040101. PubMed DOI PMC

Chiarotto G.B., Cartarozzi L.P., Perez M., Biscola N.P., Spejo A.B., Gubert F., Franca Junior M., Mendez-Otero R., de Oliveira A.L.R. Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1(G93A)) of ALS. J. Neuroinflamm. 2019;16:218. doi: 10.1186/s12974-019-1598-x. PubMed DOI PMC

Lall D., Baloh R.H. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J. Clin. Investig. 2017;127:3250–3258. doi: 10.1172/JCI90607. PubMed DOI PMC

Apolloni S., Fabbrizio P., Parisi C., Amadio S., Volonte C. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2016;53:518–531. doi: 10.1007/s12035-014-9019-8. PubMed DOI

Desarnaud F., Do Thi A.N., Brown A.M., Lemke G., Suter U., Baulieu E.E., Schumacher M. Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. J. Neurochem. 1998;71:1765–1768. doi: 10.1046/j.1471-4159.1998.71041765.x. PubMed DOI

Zhu X., Frechou M., Schumacher M., Guennoun R. Cerebroprotection by progesterone following ischemic stroke: Multiple effects and role of the neural progesterone receptors. J. Steroid Biochem. Mol. Biol. 2019;185:90–102. doi: 10.1016/j.jsbmb.2018.07.014. PubMed DOI

Gaignard P., Liere P., Therond P., Schumacher M., Slama A., Guennoun R. Role of Sex Hormones on Brain Mitochondrial Function, with Special Reference to Aging and Neurodegenerative Diseases. Front. Aging Neurosci. 2017;9:406. doi: 10.3389/fnagi.2017.00406. PubMed DOI PMC

Hedayatpour A., Shiasi M., Famitafreshi H., Abolhassani F., Ebrahimnia P., Mokhtari T., Hassanzaeh G., Karimian M., Nazparvar B., Marefati N., et al. Co-Administration of Progesterone and Melatonin Attenuates Ischemia-Induced Hippocampal Damage in Rats. J. Mol. Neurosci. 2018;66:251–260. doi: 10.1007/s12031-018-1163-6. PubMed DOI

Melcangi R.C., Giatti S., Calabrese D., Pesaresi M., Cermenati G., Mitro N., Viviani B., Garcia-Segura L.M., Caruso D. Levels and actions of progesterone and its metabolites in the nervous system during physiological and pathological conditions. Prog. Neurobiol. 2014;113:56–69. doi: 10.1016/j.pneurobio.2013.07.006. PubMed DOI

Gargiulo-Monachelli G., Meyer M., Lara A., Garay L., Lima A., Roig P., De Nicola A.F., Gonzalez Deniselle M.C. Comparative effects of progesterone and the synthetic progestin norethindrone on neuroprotection in a model of spontaneous motoneuron degeneration. J. Steroid Biochem. Mol. Biol. 2019;192:105385. doi: 10.1016/j.jsbmb.2019.105385. PubMed DOI

Kassa R.M., Bonafede R., Boschi F., Bentivoglio M., Mariotti R. Effect of physical exercise and anabolic steroid treatment on spinal motoneurons and surrounding glia of wild-type and ALS mice. Brain Res. 2017;1657:269–278. doi: 10.1016/j.brainres.2016.12.029. PubMed DOI

Crivello M., O’Riordan S.L., Woods I., Cannon S., Halang L., Coughlan K.S., Hogg M.C., Lewandowski S.A., Prehn J.H.M. Pleiotropic activity of systemically delivered angiogenin in the SOD1(G93A) mouse model. Neuropharmacology. 2018;133:503–511. doi: 10.1016/j.neuropharm.2018.02.022. PubMed DOI

Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 1994;330:585–591. doi: 10.1056/NEJM199403033300901. PubMed DOI

Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425–1431. doi: 10.1016/S0140-6736(96)91680-3. PubMed DOI

Bensimon G., Lacomblez L., Delumeau J.C., Bejuit R., Truffinet P., Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol. 2002;249:609–615. doi: 10.1007/s004150200071. PubMed DOI

Cheah B.C., Vucic S., Krishnan A., Kiernan M.C. Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis. Curr. Med. Chem. 2010;17:1942–1959. doi: 10.2174/092986710791163939. PubMed DOI

Watanabe T., Yuki S., Egawa M., Nishi H. Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 1994;268:1597–1604. PubMed

Yoshino H., Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study) Amyotroph. Lateral Scler. 2006;7:247–251. doi: 10.1080/17482960600881870. PubMed DOI

Abe K., Itoyama Y., Sobue G., Tsuji S., Aoki M., Doyu M., Hamada C., Kondo K., Yoneoka T., Akimoto M., et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Front. Degener. 2014;15:610–617. doi: 10.3109/21678421.2014.959024. PubMed DOI PMC

Abe K., Itoyama Y., Aoki M., Tsuji S., Sobue G., Doyu M., Hamada C., Doi S., Ogata K., Mizoguchi K., et al. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation) Amyotroph. Lateral Scler. Front. Degener. 2017;18:40–48. doi: 10.1080/21678421.2017.1361441. PubMed DOI

Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Tanaka M., Akimoto M., Nakamura K., et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–512. doi: 10.1016/S1474-4422(17)30115-1. PubMed DOI

Abe K., Aoki M., Tsuji S., Itoyama Y., Sobue G., Togo M., Hamada C., Sasaki H., Yabe I., Doi S., et al. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2017;18:55–63. doi: 10.1080/21678421.2017.1364269. PubMed DOI

Fortuna A., Gizzi M., Bello L., Martinelli I., Bertolin C., Pegoraro E., Corbetta M., Sorarù G. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. J. Neurol. Sci. 2019;404:47–51. doi: 10.1016/j.jns.2019.06.006. PubMed DOI

Trias E., Ibarburu S., Barreto-Núñez R., Varela V., Moura I.C., Dubreuil P., Hermine O., Beckman J.S., Barbeito L. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight. 2017;2 doi: 10.1172/jci.insight.95934. PubMed DOI PMC

Trias E., King P.H., Si Y., Kwon Y., Varela V., Ibarburu S., Kovacs M., Moura I.C., Beckman J.S., Hermine O., et al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight. 2018;3 doi: 10.1172/jci.insight.123249. PubMed DOI PMC

Trias E., Ibarburu S., Barreto-Núñez R., Babdor J., Maciel T.T., Guillo M., Gros L., Dubreuil P., Díaz-Amarilla P., Cassina P., et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflamm. 2016;13 doi: 10.1186/s12974-016-0620-9. PubMed DOI PMC

Mora J.S., Genge A., Chio A., Estol C.J., Chaverri D., Hernández M., MarÍn S., Mascias J., Rodriguez G.E., Povedano M., et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial. Amyotroph. Lateral Scler. Front. Degener. 2019 doi: 10.1080/21678421.2019.1632346. PubMed DOI

AB Science AB Science Announces That the CHMP Has Adopted a Negative Opinion for Marketing Authorization of Masitinib in ALS. [(accessed on 10 October 2019)]; Available online: https://www.globenewswire.com/news-release/2018/04/19/1482067/0/en/AB-Science-announces-that-the-CHMP-has-adopted-a-negative-opinion-for-the-marketing-authorization-of-masitinib-in-Amyotrophic-Lateral-Sclerosis.html.

Cudkowicz M.E., van den Berg L.H., Shefner J.M., Mitsumoto H., Mora J.S., Ludolph A., Hardiman O., Bozik M.E., Ingersoll E.W., Archibald D., et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): A randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–1067. doi: 10.1016/S1474-4422(13)70221-7. PubMed DOI

Pascuzzi R.M., Shefner J., Chappell A.S., Bjerke J.S., Tamura R., Chaudhry V., Clawson L., Haas L., Rothstein J.D. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;11:266–271. doi: 10.3109/17482960903307805. PubMed DOI

Ferrante K.L., Shefner J., Zhang H., Betensky R., O’Brien M., Yu H., Fantasia M., Taft J., Beal M.F., Traynor B., et al. Tolerance of high-dose (3000 mg/day) coenzyme Q10 in ALS. Neurology. 2005;65:1834–1836. doi: 10.1212/01.wnl.0000187070.35365.d7. PubMed DOI

Kaufmann P., Thompson J.L.P., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., Katz J., Rollins Y., Barohn R.J., Jackson C.E., et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009;66:235–244. doi: 10.1002/ana.21743. PubMed DOI PMC

Groeneveld G.J., Veldink J.H., Van der Tweel I., Kalmijn S., Beijer C., De Visser M., Wokke J.H.J., Franssen H., Van den Berg L.H. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. 2003;53:437–445. doi: 10.1002/ana.10554. PubMed DOI

Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Mueller G., Wermer M., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 1999;5:347–350. doi: 10.1038/6568. PubMed DOI

Pastula D.M., Moore D.H., Bedlack R.S. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst. Rev. 2012 doi: 10.1002/14651858.CD005225.pub3. PubMed DOI

Rosenfeld J., King R.M., Jackson C.E., Bedlack R.S., Barohn R.J., Dick A., Phillips L.H., Chapin J., Gelinas D.F., Lou J.S. Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph. Lateral Scler. 2008;9:266–272. doi: 10.1080/17482960802028890. PubMed DOI PMC

Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton M., Urbinelli L., Qureshi M., Zhang H., Pestronk A., et al. A clinical trial of creatine in ALS. Neurology. 2004;63:1656–1661. doi: 10.1212/01.WNL.0000142992.81995.F0. PubMed DOI

Shefner J., Cedarbaum J.M., Cudkowicz M.E., Maragakis N., Lee J., Jones D., Watson M.L., Mahoney K., Chen M., Saikali K., et al. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012;13:430–438. doi: 10.3109/17482968.2012.684214. PubMed DOI

Shefner J.M., Watson M.L., Meng L., Wolff A.A., Neals/Cytokinetics S.T. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2013;14:574–581. doi: 10.3109/21678421.2013.822517. PubMed DOI

Shefner J.M., Wolff A.A., Meng L. The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotroph. Lateral Scler. Front. Degener. 2013;14:582–585. doi: 10.3109/21678421.2013.817587. PubMed DOI

Shefner J.M., Wolff A.A., Meng L., Bian A., Lee J., Barragan D., Andrews J.A., Group B.-A.S. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2016;17:426–435. doi: 10.3109/21678421.2016.1148169. PubMed DOI

Shefner J.M., Cudkowicz M.E., Hardiman O., Cockroft B.M., Lee J.H., Malik F.I., Meng L., Rudnicki S.A., Wolff A.A., Andrews J.A. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2019 doi: 10.1080/21678421.2019.1612922. PubMed DOI

Cytokinetics Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting. [(accessed on 10 October 2019)]; Available online: https://cytokineticsinc.gcs-web.com/news-releases/news-release-details/cytokinetics-announces-results-fortitude-als-phase-2-clinical.

Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Zhang H., Andreasson K.I., Rothstein J.D., Drachman D.B. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 2006;60:22–31. doi: 10.1002/ana.20903. PubMed DOI

Gordon P.H., Cheung Y.K., Levin B., Andrews H., Doorish C., MacArthur R.B., Montes J., Bednarz K., Florence J., Rowin J., et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph. Lateral Scler. 2008;9:212–222. doi: 10.1080/17482960802195632. PubMed DOI PMC

Cudkowicz M., Bozik M.E., Ingersoll E.W., Miller R., Mitsumoto H., Shefner J., Moore D.H., Schoenfeld D., Mather J.L., Archibald D., et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat. Med. 2011;17:1652–1656. doi: 10.1038/nm.2579. PubMed DOI

Lauria G., Bella E.D., Antonini G., Borghero G., Capasso M., Caponnetto C., Chiò A., Corbo M., Eleopra R., Fazio R., et al. Erythropoietin in amyotrophic lateral sclerosis: A multicentre, randomised, double blind, placebo controlled, phase III study. J. Neurol. Neurosurg. Psychiatry. 2015;86:879–886. doi: 10.1136/jnnp-2014-308996. PubMed DOI PMC

Lauria G., Campanella A., Filippini G., Martini A., Penza P., Maggi L., Antozzi C., Ciano C., Beretta P., Caldiroli D., et al. Erythropoietin in amyotrophic lateral sclerosis: A pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph. Lateral Scler. 2009;10:410–415. doi: 10.3109/17482960902995246. PubMed DOI

Gordon P.H., Doorish C., Montes J., Mosely R.L., Diamond B., MacArthur R.B., Weimer L.H., Kaufmann P., Hays A.P., Rowland L.P., et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology. 2006;66:1117–1119. doi: 10.1212/01.wnl.0000204235.81272.e2. PubMed DOI

Meininger V., Drory V.E., Leigh P.N., Ludolph A., Robberecht W., Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. 2009;10:378–383. doi: 10.3109/17482960902803432. PubMed DOI

Aggarwal S.P., Zinman L., Simpson E., McKinley J., Jackson K.E., Pinto H., Kaufman P., Conwit R.A., Schoenfeld D., Shefner J., et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481–488. doi: 10.1016/S1474-4422(10)70068-5. PubMed DOI PMC

Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M.L., Lazzeri G., Spalloni A., Bellio N., Lenzi P., et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2008;105:2052–2057. doi: 10.1073/pnas.0708022105. PubMed DOI PMC

Verstraete E., Veldink J.H., Huisman M.H.B., Draak T., Uijtendaal E.V., Van Der Kooi A.J., Schelhaas H.J., De Visser M., Van Der Tweel I., Van Den Berg L.H. Lithium lacks effect on survival in amyotrophic lateral sclerosis: A phase IIb randomised sequential trial. J. Neurol. Neurosurg. Psychiatry. 2012;83:557–564. doi: 10.1136/jnnp-2011-302021. PubMed DOI

Morrison K.E., Dhariwal S., Hornabrook R., Savage L., Burn D.J., Khoo T.K., Kelly J., Murphy C.L., Al-Chalabi A., Dougherty A., et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339–345. doi: 10.1016/S1474-4422(13)70037-1. PubMed DOI PMC

Gordon P.H., Moore D.H., Gelinas D.F., Qualls C., Meister M.E., Werner J., Mendoza M., Mass J., Kushner G., Miller R.G. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology. 2004;62:1845–1847. doi: 10.1212/01.WNL.0000125321.92112.7E. PubMed DOI

Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurol. 2007;6:1045–1053. doi: 10.1016/S1474-4422(07)70270-3. PubMed DOI

Pontieri F.E., Ricci A., Pellicano C., Benincasa D., Buttarelli F.R. Minocycline in amyotrophic lateral sclerosis: A pilot study. Neurol. Sci. 2005;26:285–287. doi: 10.1007/s10072-005-0474-x. PubMed DOI

Miller R.G., Block G., Katz J.S., Barohn R.J., Gopalakrishnan V., Cudkowicz M., Zhang J.R., McGrath M.S., Ludington E., Appel S.H., et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol. Neuroimmunol. NeuroInflamm. 2015;2:e100. doi: 10.1212/NXI.0000000000000100. PubMed DOI PMC

Miller R.G., Zhang R., Block G., Katz J., Barohn R., Kasarskis E., Forshew D., Gopalakrishnan V., McGrath M.S. NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study. Amyotrophic Lateral Scler. Front. Degener. 2014;15:601–609. doi: 10.3109/21678421.2014.951940. PubMed DOI PMC

Lenglet T., Lacomblez L., Abitbol J.L., Ludolph A., Mora J.S., Robberecht W., Shaw P.J., Pruss R.M., Cuvier V., Meininger V. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. 2014;21:529–536. doi: 10.1111/ene.12344. PubMed DOI

Miller R., Bradley W., Cudkowicz M., Hubble J., Meininger V., Mitsumoto H., Moore D., Pohlmann H., Sauer D., Silani V., et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007;69:776–784. doi: 10.1212/01.wnl.0000269676.07319.09. PubMed DOI

Piepers S., Veldink J.H., De Jong S.W., Van Der Tweel I., Van Der Pol W.L., Uijtendaal E.V., Schelhaas H.J., Scheffer H., De Visser M., De Jong J.M.B.V., et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol. 2009;66:227–234. doi: 10.1002/ana.21620. PubMed DOI

Lacomblez L., Bensimon G., Douillet P., Doppler V., Salachas F., Meininger V. Xaliproden in amyotrophic lateral sclerosis: Early clinical trials. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2004;5:99–106. doi: 10.1080/14660820410018973. PubMed DOI

Meininger V., Bensimon G., Bradley W.G., Brooks B.R., Douillet P., Eisen A.A., Lacomblez L., Leigh P.N., Robberecht W. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2004;5:107–117. doi: 10.1080/14660820410019602. PubMed DOI

Dupuis L., Dengler R., Heneka M.T., Meyer T., Zierz S., Kassubek J., Fischer W., Steiner F., Lindauer E., Otto M., et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e37885. doi: 10.1371/journal.pone.0037885. PubMed DOI PMC

Meininger V., Genge A., van den Berg L.H., Robberecht W., Ludolph A., Chio A., Kim S.H., Leigh P.N., Kiernan M.C., Shefner J.M., et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:208–216. doi: 10.1016/S1474-4422(16)30399-4. PubMed DOI

Borasio G.D., Robberecht W., Leigh P.N., Emile J., Guiloff R.J., Jerusalem F., Silani V., Vos P.E., Wokke J.H.J., Dobbins T. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology. 1998;51:583–586. doi: 10.1212/WNL.51.2.583. PubMed DOI

Lai E.C., Felice K.J., Festoff B.W., Gawel M.J., Gelinas D.F., Kratz R., Murphy M.F., Natter H.M., Norris F.H., Rudnicki S.A. Effect of recombinant human insulin-like growth factor-I on progression of ALS: A placebo-controlled study. Neurology. 1997;49:1621–1630. doi: 10.1212/WNL.49.6.1621. PubMed DOI

Sorenson E.J., Windbank A.J., Mandrekar J.N., Bamlet W.R., Appel S.H., Armon C., Barkhaus P.E., Bosch P., Boylan K., David W.S., et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770–1775. doi: 10.1212/01.wnl.0000335970.78664.36. PubMed DOI PMC

Ludolph A.C., Schuster J., Dorst J., Dupuis L., Dreyhaupt J., Weishaupt J.H., Kassubek J., Weiland U., Petri S., Meyer T., et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018;17:681–688. doi: 10.1016/S1474-4422(18)30176-5. PubMed DOI

Theofilopoulos S., Wang Y., Kitambi S.S., Sacchetti P., Sousa K.M., Bodin K., Kirk J., Saltó C., Gustafsson M., Toledo E.M., et al. Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat. Chem. Biol. 2013;9:126–133. doi: 10.1038/nchembio.1156. PubMed DOI

Vaz A.R., Cunha C., Gomes C., Schmucki N., Barbosa M., Brites D. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration. Mol. Neurobiol. 2015;51:864–877. doi: 10.1007/s12035-014-8731-8. PubMed DOI

Elia A.E., Lalli S., Monsurrò M.R., Sagnelli A., Taiello A.C., Reggiori B., La Bella V., Tedeschi G., Albanese A. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2016;23:45–52. doi: 10.1111/ene.12664. PubMed DOI PMC

Takata M., Tanaka H., Kimura M., Nagahara Y., Tanaka K., Kawasaki K., Seto M., Tsuruma K., Shimazawa M., Hara H. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br. J. Pharmacol. 2013;170:341–351. doi: 10.1111/bph.12277. PubMed DOI PMC

Lingor P., Weber M., Camu W., Friede T., Hilgers R., Leha A., Neuwirth C., Günther R., Benatar M., Kuzma-Kozakiewicz M., et al. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front. Neurol. 2019;10:293. doi: 10.3389/fneur.2019.00293. PubMed DOI PMC

Pozzi S., Thammisetty S.S., Julien J.-P. Chronic Administration of Pimozide Fails to Attenuate Motor and Pathological Deficits in Two Mouse Models of Amyotrophic Lateral Sclerosis. Neurother. J. Am. Soc. Exp. Neurother. 2018;15:715–727. doi: 10.1007/s13311-018-0634-3. PubMed DOI PMC

Zoccolella S., Bendotti C., Beghi E., Logroscino G. Homocysteine levels and amyotrophic lateral sclerosis: A possible link. Amyotroph. Lateral Scler. 2010;11:140–147. doi: 10.3109/17482960902919360. PubMed DOI

Kaji R., Kodama M., Imamura A., Hashida T., Kohara N., Ishizu M., Inui K., Kimura J. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double-blind controlled study. Muscle Nerve. 1998;21:1775–1778. doi: 10.1002/(SICI)1097-4598(199812)21:12<1775::AID-MUS22>3.0.CO;2-V. PubMed DOI

Kaji R., Imai T., Iwasaki Y., Okamoto K., Nakagawa M., Ohashi Y., Takase T., Hanada T., Shimizu H., Tashiro K., et al. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: A long-term phase II/III randomised controlled study. J. Neurol. Neurosurg. Psychiatry. 2019;90:451–457. doi: 10.1136/jnnp-2018-319294. PubMed DOI PMC

Moreau C., Danel V., Devedjian J.C., Grolez G., Timmerman K., Laloux C., Petrault M., Gouel F., Jonneaux A., Dutheil M., et al. Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Antioxid. Redox Signal. 2018;29:742–748. doi: 10.1089/ars.2017.7493. PubMed DOI PMC

Collaborative Medicinal Development, LLC Collaborative Medicinal Development, LLC Reports that Lead Drug Modifies ALS Progression. [(accessed on 18 January 2020)]; Available online: https://www.prnewswire.com/news-releases/collaborative-medicinal-development-llc-reports-that-lead-drug-modifies-als-progression-300774250.html.

Kuo M.T.H., Beckman J.S., Shaw C.A. Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model. Neurobiol. Dis. 2019;130 doi: 10.1016/j.nbd.2019.104495. PubMed DOI

Williams J.R., Trias E., Beilby P.R., Lopez N.I., Labut E.M., Bradford C.S., Roberts B.R., McAllum E.J., Crouch P.J., Rhoads T.W., et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SODG93A mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol. Dis. 2016;89:1–9. doi: 10.1016/j.nbd.2016.01.020. PubMed DOI PMC

Benatar M., Wuu J., Andersen P.M., Atassi N., David W., Cudkowicz M., Schoenfeld D. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565–e574. doi: 10.1212/WNL.0000000000004960. PubMed DOI PMC

Johnson K.W., Matsuda K., Iwaki Y. Ibudilast for the treatment of drug addiction and other neurological conditions. Clin. Investig. 2014;4:269–279. doi: 10.4155/cli.14.8. DOI

Medicinova MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS. [(accessed on 18 January 2020)]; Available online: https://www.globenewswire.com/news-release/2018/07/09/1534969/0/en/MediciNova-Announces-Clinical-Data-from-Subgroup-Analyses-of-Completed-Clinical-Trial-of-MN-166-ibudilast-in-ALS.html.

Rao V.T.S., Khan D., Jones R.G., Nakamura D.S., Kennedy T.E., Cui Q.L., Rone M.B., Healy L.M., Watson R., Ghosh S., et al. Potential Benefit of the Charge-Stabilized Nanostructure Saline RNS60 for Myelin Maintenance and Repair. Sci. Rep. 2016;6 doi: 10.1038/srep30020. PubMed DOI PMC

Paganoni S., Alshikho M.J., Luppino S., Chan J., Pothier L., Schoenfeld D., Andres P.L., Babu S., Zürcher N.R., Loggia M.L., et al. A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle Nerve. 2019;59:303–308. doi: 10.1002/mus.26385. PubMed DOI PMC

Patten S.A., Aggad D., Martinez J., Tremblay E., Petrillo J., Armstrong G.A., La Fontaine A., Maios C., Liao M., Ciura S., et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight. 2017;2 doi: 10.1172/jci.insight.97152. PubMed DOI PMC

Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435–442. doi: 10.1016/S1474-4422(13)70061-9. PubMed DOI PMC

Martier R., Liefhebber J.M., García-Osta A., Miniarikova J., Cuadrado-Tejedor M., Espelosin M., Ursua S., Petry H., van Deventer S.J., Evers M.M., et al. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Mol. Ther. Nucleic Acids. 2019;16:26–37. doi: 10.1016/j.omtn.2019.02.001. PubMed DOI PMC

Martier R., Liefhebber J.M., Miniarikova J., van der Zon T., Snapper J., Kolder I., Petry H., van Deventer S.J., Evers M.M., Konstantinova P. Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther. Nucleic Acids. 2019;14:593–608. doi: 10.1016/j.omtn.2019.01.010. PubMed DOI PMC

Sufit R.L., Ajroud-Driss S., Casey P., Kessler J.A. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2017;18:269–278. doi: 10.1080/21678421.2016.1259334. PubMed DOI

Sawada A., Wang S., Jian M., Leem J., Wackerbarth J., Egawa J., Schilling J.M., Platoshyn O., Zemljic-Harpf A., Roth D.M., et al. Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1G93A mice. FASEB J. 2019;33:7545–7554. doi: 10.1096/fj.201802652RR. PubMed DOI PMC

Izrael M., Slutsky S.G., Admoni T., Cohen L., Granit A., Hasson A., Itskovitz-Eldor J., Krush Paker L., Kuperstein G., Lavon N., et al. Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1(G93A) and NSG animal models. Stem Cell Res. Ther. 2018;9:152. doi: 10.1186/s13287-018-0890-5. PubMed DOI PMC

Mandrioli J., Amedei A., Cammarota G., Niccolai E., Zucchi E., D’Amico R., Ricci F., Quaranta G., Spanu T., Masucci L. FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. Front. Neurol. 2019;10:1021. doi: 10.3389/fneur.2019.01021. PubMed DOI PMC

Goutman S.A., Savelieff M.G., Sakowski S.A., Feldman E.L. Stem cell treatments for amyotrophic lateral sclerosis: A critical overview of early phase trials. Expert Opin. Investig. Drugs. 2019;28:525–543. doi: 10.1080/13543784.2019.1627324. PubMed DOI PMC

Petrou P., Gothelf Y., Argov Z., Gotkine M., Levy Y.S., Kassis I., Vaknin-Dembinsky A., Ben-Hur T., Offen D., Abramsky O., et al. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. JAMA Neurol. 2016;73:337–344. doi: 10.1001/jamaneurol.2015.4321. PubMed DOI

Gothelf Y., Cudkowicz M., Berry J., Windebank A., Staff N., Owegi M., Levy Y.S., Aricha R., Mehra M., Lebovits C., et al. Safety and efficacy of transplantation of nurown (autologous mesenchymal stromal cells secreting neurotrophic factors) in patients with ALS: A phase 2 randomized double blind placebo controlled trial. Cytotherapy. 2017;19:S23. doi: 10.1016/j.jcyt.2017.02.040. DOI

Berry J., Aricha R., Kaspi H., Cudkowicz M., Windebank A., Staff N., Owegi M.A., Levy Y.S., Lebovits C., Brown R., et al. MicroRNA Changes in the NurOwn® Phase 2 ALS Randomized Clinical Trial: Relationship to Neuroprotection and Innate Immunity. [(accessed on 18 January 2020)]; Available online: https://brainstorm-cell.com/wp-content/uploads/2018/12/2018-October-NEALS-Poster-23-Berry-et-al.pdf.

The deletion of AQP4 and TRPV4 affects astrocyte swelling/volume recovery in response to ischemia-mimicking pathologies

Reactive gliosis in traumatic brain injury: a comprehensive review